Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

NIAID Data Ecosystem2026-03-10 收录

结直肠癌化疗方案

I期临床试验

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2261846 数据链接链接失效反馈

官方服务：

资源简介：

Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.

创建时间：

2018-01-15

To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.

I期临床试验

转移性结直肠癌治疗

TSB-9-W1, prepared by Taiwan Sunpan Biotechnology Co., Ltd. (TSB) is a botanical drug and applied patent in the United States (US patent No. 7,138,428 B2), Japan (Patent No. 5441947) and Taiwan (Paten

NIAID Data Ecosystem80

XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy

结直肠癌化疗方案

抗肿瘤药物疗效评估

Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous

NIAID Data Ecosystem40

Dataset from A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban

I期临床试验

药代动力学与安全性评估

The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat

NIAID Data Ecosystem30

Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

I期临床试验

人口统计与临床基线

Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

NIAID Data Ecosystem50

Table_3_Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.docx

结直肠癌化疗方案

患者来源类器官模型

BackgroundAddition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-free survival and served as the first line adjuvant chemotherapy in advanced colorectal cancer (CRC) patients.

NIAID Data Ecosystem40

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

资源简介：

相关数据集